"Pfizer"

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!